Author

admin

Browsing

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the ‘AGM’) will be webcast on May 28, 2025, at 4:30 p.m. EDT.

Cardiol Therapeutics’ 2025 AGM

When: May 28, 2025, at 4:30 p.m. EDT
Where: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161

Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com/investors/events-presentations/.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253470

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

(TheNewswire)

Edmonton, Alberta May 27, 2025 TheNewswire – Bitcoin Well Inc. (‘ Bitcoin Well ‘ or the ‘ Company ‘) ( TSXV: BTCW; OTCQB: BCNWF ), the non-custodial bitcoin business on a mission to enable independence announces a first-of-its-kind Nostr integration to allow Bitcoin Well customers in the USA to purchase bitcoin directly from their Nostr profile.

Key points:

How it Works:

  • The purchase uses the customers Cash Balance, and bitcoin is sent to an existing Lightning Wallet for security.

Why it Matters:

  • It aligns with the company’s mission to simplify self-custody bitcoin purchases.

Nostr’s Role:

    Impact:

      This move continues to position Bitcoin Well as a leader in freedom technologies by making bitcoin in self custody the standard. For detailed information keep reading, or visit https://bitcoinwell.com/blog/buy-bitcoin-with-nostr

      Why does this matter?

      Social media, specifically Nostr, is one of the most impactful technologies of our generation. Our lives, our communities and our personalities have transitioned to the digital realm. Bitcoin Well has now enabled everyone in the USA to buy bitcoin safely, directly from their Nostr account.

      In doing this, Bitcoin Well has become the easiest place to buy bitcoin! With a simple message, our customers in the USA can now purchase bitcoin in a matter of seconds; without logging in to their Bitcoin Well account.

      ‘This is a great achievement for our team!’ said Adam O’Brien, founder and CEO of Bitcoin Well. ‘We are deeply committed to make buying bitcoin directly to self custody better than using a custodial exchange. This is a huge step in the right direction. We are meeting bitcoiners where they are and allowing them to buy bitcoin safely.’

      How does it work?

      Once a customer links their npub (the social network identifier used by the Nostr protocol) to their Bitcoin Well account from their profile page , they can DM the Bitcoin Well Nostr profile with the command words to purchase bitcoin. The command words are:

      • /buy $21.00 (or any dollar amount)

      • /stack 69,000 sats (or any amount of sats)

      After a simple ‘/confirm’ response, the customer’s Cash Balance in their Bitcoin Well account will be used to buy bitcoin, and the bitcoin will be sent to their predetermined payment address over the Lightning Network.

      To maintain security, bitcoin can only be sent to a Lightning Wallet which has already been added to their Bitcoin Well account.

      What is Nostr?

      Nostr is a decentralized social media protocol which is censorship resistant and runs on a network of relays, rather than centralized servers. This means that the users of the platform control the posts (known as ‘notes’) rather than the owner of the social media platform. This is particularly impactful for the Company because it means we have full control over our message servers; which hasn’t been the case in the past.

      Historically, our messaging platforms have prohibited us from creating a ‘text to buy’ type of service. Even our payment providers have been limited in the past. With the addition of the Nostr protocol we can be certain that this level of censorship will not impact us, or our customer’s ability to buy bitcoin. Furthermore, there is an added layer of protection for the customer’s privacy.

      About Bitcoin Well

      Bitcoin Well is on a mission to enable independence. We do this by making bitcoin useful to everyday people to give them the convenience of modern banking and the benefits of bitcoin. We like to think of it as future-proofing money. Our existing Bitcoin ATM and Online Bitcoin Portal business units drive cash flow to help fund this mission.

      Join our investor community and follow us on Nostr , , and to keep up to date with our business.

      Bitcoin Well contact information

      To book a virtual meeting with our Founder & CEO Adam O’Brien please use the following link: https://bitcoinwell.com/meet-adam

      For additional investor & media information, please contact:

      Adam O’Brien

      Tel: 1 888 711 3866

      ir@bitcoinwell.com

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

      Forward-looking information

      Certain statements contained in this news release may constitute forward-looking information, which is often, but not always, identified by the use of words such as ‘anticipate’, ‘plan’, ‘estimate’, ‘expect’, ‘may’, ‘will’, ‘intend’, ‘should’, or the negative thereof and similar expressions. All statements herein other than statements of historical fact constitute forward-looking information including, but not limited to, statements in respect of Bitcoin Well’s business plans, strategy and outlook. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information including, but not limited to, the risk factors described in Bitcoin Well’s annual information form and management’s discussion and analysis for the year ended December 31, 2024. Forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents Bitcoin Well’s expectations as of the date hereof and is subject to change. Bitcoin Well disclaims any intention or obligation to revise any forward-looking information, except as required by applicable securities legislation.

      Copyright (c) 2025 TheNewswire – All rights reserved.

      News Provided by TheNewsWire via QuoteMedia

      This post appeared first on investingnews.com

      Blue Sky Uranium (TSXV:BSK,OTC:BKUCF)provides investors with a compelling opportunity to gain exposure to the uranium market through its strategic foothold in Argentina’s emerging uranium sector. Backed by a substantial resource base, robust project economics, and a strong joint venture partnership, the company has a clear pathway to potential production.

      Blue Sky Uranium is positioning itself as a leading force in uranium exploration and development in Argentina. As part of the renowned Grosso Group—pioneers in Argentine mineral exploration since 1993 and contributors to four major mineral discoveries—Blue Sky leverages decades of in-country expertise and well-established local partnerships.

      The company’s flagship Amarillo Grande Project is a unique, company-led discovery marking Argentina’s newest uranium-vanadium district. Spanning over 145 kilometers and covering more than 300,000 hectares in Rio Negro Province, this district-scale project hosts the largest NI 43-101-compliant uranium resource in Argentina at its Ivana deposit. With this strategic asset, Blue Sky is well-positioned to become the country’s first domestic uranium supplier, supporting a growing nuclear energy program that currently relies entirely on imported fuel.

      Company Highlights

      • Significant Uranium Resource: Controls the largest NI 43-101 compliant uranium resource in Argentina with 17 Mlbs U3O8 in indicated resources and 3.8 Mlbs in inferred resources, plus valuable vanadium credits.
      • Low-cost Production Potential: Near-surface mineralization with no blasting required, hosted in loosely consolidated sediments, making for potentially low mining costs.
      • Strategic JV Partnership: Secured an earn-in agreement with COAM to advance the Ivana deposit with no funding required by Blue Sky through development. COAM will spend up to US$35 million to earn up to a 49.9 percent interest, and can further earn up to 80 percent by funding development costs to production (up to US$160 million).
      • Strong Uranium Market Fundamentals: Global uranium market faces supply deficits with increasing demand from nuclear power generation, with prices strengthening significantly since 2023.
      • Domestic Market Opportunity: Argentina has three operational nuclear plants with others under construction or planned, yet imports all uranium for fuel. National legislation guarantees purchase of domestically produced uranium.
      • ISR Project Pipeline: New projects in the Neuquen Basin provide future growth through potential in-situ recovery operations, a method that produces 57 percent of the world’s uranium with minimal environmental impact.

      This Blue Sky Uranium profile is part of a paid investor education campaign.*

      Click here to connect with Blue Sky Uranium (TSXV:BSK) to receive an Investor Presentation

      This post appeared first on investingnews.com

      NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

      Saga Metals Corp. (the ‘Company’ or ‘SAGA’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery in Canada, is pleased to announce that it has closed a first tranche (the ‘ First Tranche ‘) of its non-brokered private placement announced on May 2, 2025 (the ‘ Offering ‘) for gross proceeds of $1,239,700.10. The Company has also received a 30-day extension to close the Offering from the TSX Venture Exchange, and accordingly expects to close the final tranche of the Offering on or before June 25, 2025.

      On closing of the First Tranche, the Company received gross proceeds of $444,200.10 from the issuance of 1,480,667 flow-through units at a price of $0.30 per unit (‘ FT Units ‘) and $795,500 from the issuance of 3,182,000 hard dollar units at a price of $0.25 per unit (‘ HD Units ‘).

      Each FT Unit consists of one flow-through common share (a ‘ FT Share ‘) as defined in subsection 66(15) of the Income Tax Act (Canada) (the ‘ Tax Act ‘), and one transferable common share purchase warrant (a ‘ Warrant ‘). Each Warrant will entitle its holder to purchase one common share in the capital of the Company (a ‘ Warrant Share ‘) at a price of $0.50 for 24 months from the closing date of the Offering (the ‘ Closing Date ‘). The Warrants and the Warrant Shares underlying the FT Units will not qualify as ‘flow-through shares’ under the Tax Act.

      Each HD Unit consists of one common share (a ‘ HD Share ‘) and one Warrant.

      All securities issued in connection with the First Tranche are subject to a hold period of four months and one day following the Closing Date pursuant to applicable securities laws.

      In connection with the First Tranche, the Company paid an aggregate of $31,710.01 in finder’s fees and issued 108,616 finder’s warrants (each, a ‘ Finder’s Warrant ‘) to certain finders. Each Finder’s Warrant entitles the holder thereof to purchase one common share of the Company at a price of $0.50 per share for a period of 24 months from its date of issue.

      Each of the Warrants and Finder’s Warrants will be subject to the right of the Company to accelerate the expiry date of the Warrants and Finder’s Warrants to a date that is 30 days following dissemination of a news release announcing such acceleration if, at any time, after the Closing Date, the closing price of the Company’s common shares equals or exceeds $0.75 for a period of ten consecutive trading days on the TSX Venture Exchange.

      The gross proceeds from the FT Units will be used by the Company for ‘Canadian exploration expenses’ that are ‘flow-through critical mineral mining expenditures’ (as such terms are defined in the Tax Act) on the Company’s Labrador, Canada properties. The net proceeds of the HD Units will be used by the Company for administrative and general working capital.

      Certain insiders of SAGA participated in the First Tranche, acquiring an aggregate of 442,000 HD Units for aggregate gross proceeds of $110,500. Participation of such insiders in the Offering constitutes a ‘related party transaction’ as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (‘ MI 61-101 ‘) and is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities issued to the insiders nor the consideration paid by the insiders exceeded 25% of SAGA’s market capitalization.

      The securities of SAGA have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘ U.S. Securities Act ‘), or any state securities laws, and may not be offered or sold, within the United States, unless exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws are available.

      No securities regulatory authority has reviewed or approved of the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of SAGA in any jurisdiction in which such offer, solicitation or sale would be unlawful.

      About Saga Metals Corp.

      Saga Metals Corp. is a North American mining company focused on the exploration and discovery of critical minerals that support the global transition to green energy. The company’s flagship asset, the Double Mer Uranium Project, is located in Labrador, Canada, covering 25,600 hectares. This project features uranium radiometrics that highlight an 18km east-west trend, with a confirmed 14km section producing samples as high as 0.428% U 3 O 8 and uranium uranophane was identified in several areas of highest radiometric response (2024 Double Mer Technical Report).

      In addition to its uranium focus, SAGA owns the Legacy Lithium Property in Quebec’s Eeyou Istchee James Bay region. This project, developed in partnership with Rio Tinto, has been expanded through the acquisition of the Amirault Lithium Project. Together, these properties cover 65,849 hectares and share significant geological continuity with other major players in the area, including Rio Tinto, Winsome Resources, Azimut Exploration, and Loyal Lithium.

      SAGA also holds additional exploration assets in Labrador, where the company is focused on the discovery of titanium, vanadium, and iron ore. With a portfolio that spans key minerals crucial to the green energy transition, SAGA is strategically positioned to play an essential role in the clean energy future.

      On Behalf of the Board of Directors

      Mike Stier, Chief Executive Officer

      For more information, contact:
      Saga Metals Corp.
      Investor Relations
      Tel: +1 (778) 930-1321
      Email: info@sagametals.com
      www.sagametals.com

      The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

      Cautionary Disclaimer

      This news release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts. Forward-looking statements are often identified by terms such as ‘will’, ‘may’, ‘should’, ‘anticipates’, ‘expects’, ‘believes’, and similar expressions or the negative of these words or other comparable terminology. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. In particular, this news release contains forward-looking information pertaining to the Company’s plans and objectives in respect of the terms and conditions of the Offering, the gross proceeds of the Offering, the use of proceeds from the Offering, and the anticipated closing dates of additional tranches of the Offering and the Offering. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, changes in the structure of the Offering, the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, environmental risks, limitations on insurance coverage, risks and uncertainties involved in the mineral exploration and development industry, and the risks detailed in the Company’s final prospectus in Manitoba and amended and restated final prospectus for British Columbia, Alberta and Ontario dated August 30, 2024, filed under its SEDAR+ profile at www.sedarplus.ca, and in the continuous disclosure filings made by the Company with securities regulations from time to time. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable securities law.

      News Provided by GlobeNewswire via QuoteMedia

      This post appeared first on investingnews.com

      Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the ‘Company’ or ‘Spearmint’) announces that it intends to complete a consolidation of its issued and outstanding common shares (the ‘Shares’) on the basis of one new Share (a ‘Post-consolidated Share’) for every ten currently outstanding Shares (the ‘Consolidation’). The Company also announces it intends to change its name and its trading symbol in connection with the proposed Consolidation.

      Completion of the Consolidation, name change and symbol change are subject to approval by the Canadian Securities Exchange (the ‘CSE‘). The effective date of the Consolidation, name change and symbol change will be announced in a subsequent news release.

      It is anticipated that the Consolidation will reduce the number of outstanding Shares from 287,828,583 Shares to approximately 28,782,858 Post-consolidated Shares, subject to adjustment for rounding. The Board of Directors of the Company believes that the consolidation of the Shares will both enhance the marketability of the Company as an investment and better position the Company to raise the funds necessary to execute the Company’s business plan.

      No fractional Post-consolidated Shares will be issued as a result of the Consolidation. As required under the Business Corporations Act (BC), any fractional Shares remaining after the Consolidation that are less than one half of a Share will be cancelled and any fractional Shares that are at least one half of a Share will be rounded up to one whole Share.

      The exercise price and number of Shares of the Company, issuable upon the exercise of outstanding options and warrants and conversion of outstanding convertible debentures, will be proportionally adjusted upon the implementation of the proposed Consolidation in accordance with the terms thereof.

      Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

      Contact Information
      Tel: 1604646-6903
      www.spearmintresources.ca

      info@spearmintresources.ca

      ‘James Nelson’
      President
      Spearmint Resources Inc.

      Forward-Looking Statements

      This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward-looking statements in this press release include that the Company intends to consolidate its share capital. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Risks that could change or prevent these statements from coming to fruition include that the Company may not obtain approval for the Consolidation from the CSE. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

      To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253436

      News Provided by Newsfile via QuoteMedia

      This post appeared first on investingnews.com

      NEWYou can now listen to Fox News articles!

      It was hard to concentrate in my congressional office because I could overhear a lively interview with conservative media host Glenn Beck through the thin wall. You might assume I work for a Republican, but I’m chief of staff to progressive California Congressman Ro Khanna.

      What if I told you it was one of our best interviews in recent months? 

      They disagreed on President Trump’s deportation efforts and USAID funding, but they agreed on revitalizing manufacturing and leading against China. The headline for the interview read, ‘Progressive Democrat sits down with Glenn Beck despite disagreements: ‘We’re all Team America.’’ We agreed he’d return soon.

      There’s debate about whether Democrats need a stronger message or more robust left-wing media. But what Democrats really need is to relearn the art of persuasion—not just crafting a compelling message, but figuring out how to make it cut through today’s crowded media landscape.

      Democrats don’t need a ‘left-wing Joe Rogan.’ We need to persuade the real one, along with Americans nationwide, that we share common ground and are worth supporting. 

      I know it’s possible because I saw Ro begin that process with Glenn Beck. They didn’t agree on everything, but the conversation opened a door. That’s persuasion: not instant conversion, but showing up, listening, and finding places to start.

      Our leaders are too often surrounded by chattering consultants obsessed with poll-tested messages and terrified of ruffling feathers. Every morning, I get dozens of emails urging me to tell Americans that MAGA Republicans are trying to take away their healthcare. I believe it! But it takes more than one line to convince people. We need specifics, facts, and a clear vision of what Democrats stand for.

      Ro has been building this foundation for years. He’s traveled to dozens of states, partnering with Silicon Valley to expand tech opportunities, and since the election, held town halls in Republican districts—not to preach, but to listen. At a recent Allentown, Pennsylvania, event, Ro spoke with the Trump supporters protesting outside about his bipartisan bill to lower prescription drug costs. By the end, they came inside—and applauded. 

      Having a message is just the first step. The next challenge is breaking through today’s media ecosystem—can it go viral on social media, get picked up by the press, or reach broader audiences, and still land? Amplification matters equally.

      It’s undeniable that Republicans have invested significantly more time and resources into building a powerful online ecosystem to reach voters. To overcome that right now, Democrats need to be fearless. Flood the zone, reach people where they are, win them over. Download TikTok, hire a talented, chronically online 22-year-old to post on subreddits, and create a Substack. Talk to Mehdi Hasan in the morning and Laura Ingraham in the evening. Write an op-ed for Fox News Digital.

      It’s not about giving anyone a platform or legitimacy—their platforms already exist, and their audiences view them as legitimate. It’s about using those platforms to share our message and tailoring how we communicate to different audiences without compromising our values.

      We also need to balance between viral moments with nuanced messages about complicated issues. Ro’s prescription drug bill has gained traction on X and Reddit. But his core vision—a new economic patriotism focused on 21st century solutions for the economic success of every community including new factories and AI academies—hasn’t taken off online the same way. Yet, in longer-form interviews and podcasts, it’s met with enthusiasm. Both messages matter, and we need to find the right time and place for each.

      After all, Joe Rogan supported Bernie Sanders in the 2020 presidential election. When he drifted toward Donald Trump, we shrugged and said he was gone for good. Why not try again with a tailored message and an eye toward persuasion? 

      Joe, if you’re reading this, I have a pitch for you. 

      This post appeared first on FOX NEWS

      President Donald Trump told journalists that he was ‘not happy’ with Russia’s recent large-scale strike against Ukraine while speaking to the press on Sunday.

      Speaking to reporters at Morristown Municipal Airport in New Jersey, Trump accused Putin of ‘killing a lot of people’ in the attack, which was launched on Sunday afternoon.

      I’m not happy with what Putin is doing,’ Trump explained. ‘He’s killing a lot of people, and I don’t know what the hell happened to Putin.’ 

      ‘I’ve known him a long time, always gotten along with him, but he’s sending rockets into cities and killing people, and I don’t like it at all,’ he added.

      Trump said that Putin was ‘shooting rockets into Kyiv and other cities’ in the middle of negotiations.

      ‘I don’t like what Putin is doing. Not even a little bit,’ the president emphasized. ‘He’s killing people. And something happened to this guy.’

      Trump’s comments came after Russian forces launched hundreds of drones and missiles at Ukrainian cities overnight. The attack, which has been called the largest aerial attack of the war so far, targeted the Ukrainian capital of Kyiv.

      Ukrainian officials said that at least 12 people were killed and dozens more were injured.

      Though past strikes have proven more deadly, the attack is the largest-scale aerial assault of the war in terms of the number of weapons: 298 drones and 69 missiles were launched.

      In a post on Telegram, Ukrainian President Volodymyr Zelenskyy called for an international response to the attack.

      ‘The silence of America, the silence of others in the world only encourages Putin,’ he wrote on Telegram. ‘Every such terrorist Russian strike is reason enough for new sanctions against Russia.’

      Reuters and Fox News Digital’s Brooke Curto and Kyle Schmidbauer contributed to this report.

      This post appeared first on FOX NEWS

      President Donald Trump backed several House Republicans for reelection in Truth Social posts on Sunday, expressing support for Reps. Andrew Garbarino of New York, Troy Downing of Montana, Guy Reschenthaler of Pennsylvania, and Bryan Steil of Wisconsin.

      Each lawmaker received an individual post from Trump, and each post declared that the given lawmaker has Trump’s endorsement.

      Republicans currently hold the majority in the House, but the 2026 midterms will determine whether the GOP maintains control of the chamber during the tail end of Trump’s second term in office.

      Trump’s show of support for Garbarino comes after the congressman failed to cast a vote on the ‘One Big Beautiful Bill Act’ that passed the House last week. 

      House Speaker Mike Johnson said that ‘Garbarino did not make it in time,’ but had fallen asleep.

      ‘I am proud to have been the leading voice on Long Island during negotiations on this key reconciliation bill. I fought to lift the cap on SALT and ensure hardworking Long Island families see the benefits of this important legislation. I was moments away from the House floor, to vote ‘yes,’ when the vote was closed,’ Garbarino said in a statement, according to reports. 

      ‘While I am frustrated that the vote was closed before I was able to cast my vote, I am proud of the work we accomplished to deliver huge results for Long Island. I congratulate President Trump on getting this bill passed and look forward to voting ‘yes’ when it comes back to the House floor from the Senate,’ Garbarino noted.

      Fox News Digital reached out to Garbarino’s office on Monday morning but did not receive a response by the time of publication.

      ‘Thank you, Mr. President, it’s an honor to serve NY-02,’ Garbarino said in a Sunday night post on X in response to the president’s endorsment.

      This post appeared first on FOX NEWS

      Despite assurances from Trump administration officials that farmers will not be impacted by its attempts to reduce environmental chemical exposure from foods, agricultural leaders have been expressing concern that the move will explode costs for farmers and more than double the cost of food. 

      The administration’s Make America Healthy Again (MAHA) Commission, made up of many of President Donald Trump’s political appointees and closest policy advisors, released an assessment strategizing how they will tackle childhood chronic diseases, such as obesity and mental health challenges. Part of the report’s focus is on children’s chemical exposure from our foods, which the report says is linked to developmental issues and chronic diseases.   

      Amid the report’s release, farm groups have expressed concern over the MAHA agenda’s focus on pesticides. They have said that if the administration starts clamping down on widely used pesticides, crop yields would decline, input costs would surge and food costs would more than double.

      ‘Farmers are already facing a host of challenges—uncertainty about their access to critical crop protection products shouldn’t be added to the list,’ said Elizabeth Burns-Thompson, Executive Director of the Modern Ag Alliance. ‘Crop protection tools are not only safe, they are essential to food security, affordability, and the survival of family farms all across this country. Losing access to these critical inputs would be a devastating setback to American agriculture.’

      Officials from the MAHA Commission sought to reassure farmers at an event releasing their assessment on childhood chronic diseases on Thursday. Agriculture Secretary Brooke Rollins said that ‘at the center’ of the MAHA agenda is ‘making American agriculture great again.’

      ‘We love our farmers, and we want to pay respect to our farmers. And we always will,’ President Trump added at the Thursday event from the White House. ‘We won the farmers by a lot in the election, and every election, all three elections – and we won by a lot. I will never forget that. And they are foremost in our thought.’

      But some farmers are still expressing concern.

       

      ‘The Make America Healthy Again Report is filled with fear-based rather than science-based information about pesticides. We are deeply troubled that claims of this magnitude are being made without any scientific basis or regard for a long history of EPA expert evaluations of these products,’ the National Corn Grower’s Alliance (NCGA) said. ‘We call on the administration to respect the existing body of science on pesticides and, moving forward, to include America’s farmers in discussion as this process evolves.’ 

      According to a statement put out by the Modern Ag Alliance, pesticides are ‘rigorously tested’ by the federal government, noting that in the case of glyphosate – mentioned multiple times in the MAHA report – it is one of the most thoroughly studied pesticides of its kind. 

      They said that if the MAHA report drives future policy decisions it would hurt farmers and more than double the cost of food.

      ‘Without glyphosate—the most widely used weed-fighting tool by U.S. farmers—crop yields would decline, input costs would surge by 150%, and food inflation would more than double,’ the group said. ‘When Sri Lanka prohibited the use of synthetic pesticides and fertilizers in 2021, crop yields fell by over 50%, forcing the government to import massive amounts of food just to meet basic needs. We should be focused on moving American agriculture—and the country—forward.’

      Health Secretary Robert F. Kennedy Jr., who has been a vocal opponent against the dangerous health impacts of under-regulated pesticides even before he was the MAHA Commission’s leader, said last week in a Senate hearing that ‘we cannot take any step that will put a single farmer in this country out of business.’

      ‘There’s a million farmers who rely on glyphosate,’ he said. ‘100% of corn in this country relies on glyphosate. We are not going to do anything to jeopardize that business model.’ 

      The MAHA report reiterates the economic importance of protecting farmers, but it also lists glyphosate in an infographic of ‘Chemical Classes and Common Exposure Pathways’ and says research studies have shown it can cause a range of health effects. It also lists atrazine and other chemicals as dangerous to childhood health.   

      MAHA Commission officials have said that part of the administration’s focus will be a return to the gold standard of science, but the NCGA said the focus on certain widely-used pesticides, such as atrazine and glyphosate, goes against ‘decades of extensive research and testing.’

      ‘If the administration’s goal is to bring more efficiency to government, then why is the secretary of Health and Human Services duplicating efforts by raising questions about pesticides that have been answered repeatedly through research and reviews by federal regulatory bodies?’ the group questioned.

      Jennifer Galardi, a senior policy analyst focused on health and wellness issues at the Heritage Foundation, took a more balanced view of the MAHA commission’s strategy towards pesticides like glyphosate, noting that it appeared to thread the needle between supporting farmers and trying to ensure America’s food supply is safe and free of chemicals that could impact child health. 

      ‘The MAHA Commission Report seems to carefully examine competing issues in a very complex agricultural debate: the potential that crop protection tools as they’re referred to in the report may cause adverse health outcomes and the desire to protect the economic interests of farmers and the country,’ Galardi said. ‘However, everyone should agree that the companies that manufacture products such as glyphosate and GMO’s shouldn’t have undue influence over the research upon which sound policy is based. The American public should demand transparency around these decisions.’

      Galardi posited that, due to the tension around the issue of pesticides, the MAHA Commission may decide to go after ‘low-hanging fruit,’ such as improving children’s diets and lack of physical activity, which, she said, are big drivers of obesity and metabolic dysfunction.

      In response to this article, a USDA spokesperson sent the following statement from Secretary Rollins:

      ‘We must do more to improve the health outcomes of our kids and families, and President Trump knows agriculture is at the heart of the solution. America’s farmers and ranchers dedicate their lives to the noble cause of feeding their country and the world, and in doing so have created the safest and most abundant and affordable food supply in the world. We are working to make sure our kids and families are consuming the healthiest food we produce. I look forward to continuing to work with Secretary Kennedy and other members of the MAHA Commission to improve our nation’s health.’

      White House spokesman Kush Desai, in a separate statement, echoed Rollins’ sentiment about the importance of agriculture and farmers when it comes to executing the MAHA mission. He also reiterated that the MAHA movement is grounded in ‘Gold Standard of Science.’

      ‘The guiding principle of President Trump’s movement to Make America Healthy Again is the Gold Standard of Science, and everyone from America’s farmers to everyday parents are critical for the success of this movement,’ Desai said. ‘The MAHA Commission’s report is a historic step by our government to, for the first time, comprehensively review the latest evidence and research of what we know – and what we don’t know – is driving the health crisis afflicting America’s children.’

      This post appeared first on FOX NEWS